UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis

Cell, 2006-07, Vol.126 (1), p.121-134

2006

Volltextzugriff (PDF)

Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo

Oncogene, 2004-04, Vol.23 (19), p.3328-3337

2004

Volltextzugriff (PDF)

The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP

Nature structural & molecular biology, 2007-10, Vol.14 (10), p.912-920

2007

Volltextzugriff (PDF)

iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53

Nature genetics, 2006-10, Vol.38 (10), p.1133-1141

2006

Volltextzugriff (PDF)

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

Cancer cell, 2003-04, Vol.3 (4), p.387-402

2003

Volltextzugriff (PDF)

Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score

Supportive care in cancer, 2011-11, Vol.19 (11), p.1823-1830

2011

Volltextzugriff (PDF)

Epigenetic Inactivation Implies Independent Functions for Insulin-like Growth Factor Binding Protein (IGFBP)-Related Protein 1 and the Related IGFBPL1 in Inhibiting Breast Cancer Phenotypes

Clinical cancer research, 2007-07, Vol.13 (14), p.4061-4068

2007

Volltextzugriff (PDF)

Concomitant inactivation of p53 and Chk2 in breast cancer

Oncogene, 2002-02, Vol.21 (9), p.1316-1324

2002

Volltextzugriff (PDF)

p53 family members and chemoresistance in cancer: what we know and what we need to know

Drug resistance updates, 2003-12, Vol.6 (6), p.323-328

2003

Volltextzugriff (PDF)

A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer

Cancer epidemiology, biomarkers & prevention, 2006-10, Vol.15 (10), p.1914-1919

2006

Volltextzugriff (PDF)

The p53 pathway in breast cancer

Breast cancer research : BCR, 2002-01, Vol.4 (2), p.70-76, Article 70

2002

Volltextzugriff (PDF)

Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer

Cancer cell, 2008-02, Vol.13 (2), p.91-104

2008

Volltextzugriff (PDF)

Functional regulation of p73 and p63: development and cancer

Trends in biochemical sciences (Amsterdam. Regular ed.), 2003-12, Vol.28 (12), p.663-670

2003

Volltextzugriff (PDF)

The p53 network in head and neck cancer

Oral Oncology, 2003-04, Vol.39 (3), p.222-231

2003

Volltextzugriff (PDF)

Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine

Cancer, 2005-03, Vol.103 (5), p.994-999

2005

Volltextzugriff (PDF)

Carboplatin and Weekly Paclitaxel in Non-small Cell Lung Cancer Patients Unfit for or Pretreated with Chemotherapy

Anticancer research, 2005-05, Vol.25 (3C), p.2555-2559

2005

Volltextzugriff (PDF)

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter

The Journal of clinical investigation, 2010-08, Vol.120 (8), p.2842-2857

2010

Volltextzugriff (PDF)

Coincident inactivation of 14-3-3σ and p16INK4a is an early event in vulval squamous neoplasia

Oncogene, 2002-03, Vol.21 (12), p.1876-1881

2002

Volltextzugriff (PDF)

MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer

Oral oncology, 2012-07, Vol.48 (7), p.602-607

2012

Volltextzugriff (PDF)

SERMs in chemoprevention of breast cancer

European journal of cancer (1990), 2005-09, Vol.41 (13), p.1980-1989

2005

Volltextzugriff (PDF)

Abstract 3873: Genetic and epigenetic determinants of outcome in locally advanced head-and-neck cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3873-3873

2011

Volltextzugriff (PDF)

Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity

Cancer research (Chicago, Ill.), 2002-04, Vol.62 (7), p.2072-2076

2002

Volltextzugriff (PDF)

TP53 mutations in familial breast cancer: Functional aspects

Human mutation, 2003-03, Vol.21 (3), p.301-306

2003

Volltextzugriff (PDF)

Concomitant inactivation of p53 and Chk2 in breast cancer

Oncogene, 2002-02, Vol.21 (9), p.1316-1324

2002

Volltextzugriff (PDF)

Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: A pharmacology-guided schedule

International journal of radiation oncology, biology, physics, 2006-11, Vol.66 (3), p.731-737

2006

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(38)
Dissertationen
(1)

Sprache

Englisch
(39)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Humans
(29)
Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Female
(20)
Oncology
(20)
Biological And Medical Sciences
(17)
Medical Sciences
(13)
Tumors
(11)
Adult
(10)
Aged
(10)
Male
(10)
Middle Aged
(10)
Mutation
(10)
Chemotherapy
(8)
P53
(8)
Breast Cancer
(7)
Carcinoma, Squamous Cell - Genetics
(7)
Tumor Suppressor Protein P53 - Genetics
(7)
Cell Biology
(6)
Cell Line, Tumor
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Oncogene
(7)
Cancer Research
(4)
Anticancer Research
(3)
Cancer Cell
(2)
Cell
(2)
European Journal Of Cancer
(2)
Oral Oncology
(2)
The Journal Of Clinical Investigation
(2)
Breast Cancer Research : Bcr
(1)
Cancer
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis

Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo

The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP

iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score

Epigenetic Inactivation Implies Independent Functions for Insulin-like Growth Factor Binding Protein (IGFBP)-Related Protein 1 and the Related IGFBPL1 in Inhibiting Breast Cancer Phenotypes

Concomitant inactivation of p53 and Chk2 in breast cancer

p53 family members and chemoresistance in cancer: what we know and what we need to know

A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer

The p53 pathway in breast cancer

Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer

Functional regulation of p73 and p63: development and cancer

The p53 network in head and neck cancer

Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine

Carboplatin and Weekly Paclitaxel in Non-small Cell Lung Cancer Patients Unfit for or Pretreated with Chemotherapy

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter

Coincident inactivation of 14-3-3σ and p16INK4a is an early event in vulval squamous neoplasia

MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer

SERMs in chemoprevention of breast cancer

Abstract 3873: Genetic and epigenetic determinants of outcome in locally advanced head-and-neck cancer

Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity

TP53 mutations in familial breast cancer: Functional aspects

Concomitant inactivation of p53 and Chk2 in breast cancer

Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: A pharmacology-guided schedule

Suchergebnisse filtern